1 March 2021 - Diabetes drug is also effective in symptomatic chronic heart failure with reduced pump function. However, the additional benefit cannot be quantified due to the limited amount of data.

Dapagliflozin, which has been approved against type 2 diabetes since 2012, has also been approved for the treatment of adults with symptomatic chronic heart failure with a reduced ejection fraction of the heart since November 2020. 

In an early benefit assessment, the IQWiG has examined the advantages and disadvantages of this active ingredient for people with this disease.

Read IQWiG press release